Innate Pharma and Sobi Finalize Strategic Partnership with $75M Milestone

Key Facts

1Innate Pharma announced that its strategic partnership with Sobi is now effective following the completion of closing conditions.

2The transaction closing triggers a payment of USD 75 million to Innate Pharma.

In a move reflecting the ongoing consolidation of strategic alliances in the biotech sector, Innate Pharma announced that its partnership with Sobi has officially become effective. The activation follows the fulfillment of all closing conditions, including the expiration of necessary antitrust waiting periods. This partnership centers on the licensing of lacutamab for T-cell lymphoma, marking a significant milestone in the company's strategic execution.

According to reports, the finalization of the transaction triggers an immediate payment of USD 75 million to Innate Pharma. This substantial cash injection stems from the agreement originally announced on August 10, 2026. Per market dynamics, such licensing milestones are critical for oncology-focused firms to sustain their research and development pipelines without immediate recourse to equity markets.

Monitoring the equity performance, IPHA shares stood at $1.85 (at close September 14, 2026), having traded between a day high of $1.90 and a low of $1.81. Investors will be watching for how this capital infusion supports upcoming clinical milestones, as the current economic calendar shows no immediate sector-specific catalysts following the recent European Central Bank interest rate decision.